WP
BPMC

WealthPLAN Partners’s Blueprint Medicines BPMC Stock Holding History

WealthPLAN Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-65
Closed -$4.11K – 414
2023
Q2 		$4.11K Hold
65
– – ﹤0.01% 950
2023
Q1 		$2.92K Buy
+65
New +$2.93K ﹤0.01% 1084

Other funds holding BPMC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

WealthPLAN Partners's BPMC Position: Q3 2023 in Review

WealthPLAN Partners sold out of Blueprint Medicines (BPMC) in Q3 2023, closing a stake of 65 shares — an estimated $4.11K sold.

WealthPLAN Partners first reported a position in BPMC in Q1 2023 and held it in 2 quarters. The position peaked at $4.11K in Q2 2023. 220 funds tracked by Wall St. Rank hold BPMC as of Q3 2023.

  • WealthPLAN Partners reported no remaining Blueprint Medicines position as of Q3 2023 after selling out during the quarter.
  • WealthPLAN Partners sold 65 Blueprint Medicines shares in Q3 2023, an estimated $4.11K.
  • WealthPLAN Partners first reported a position in Blueprint Medicines in Q1 2023 and held it in 2 quarters.
  • WealthPLAN Partners's Blueprint Medicines position peaked at $4.11K in Q2 2023.
  • 220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2023.

Based on WealthPLAN Partners's 13F filing for Q3 2023, filed 2 Nov 2023.